Long-term rescue of a familial hypertrophic cardiomyopathy caused by a mutation in the thin filament protein, tropomyosin, via modulation of a calcium cycling protein

Journal of Molecular and Cellular Cardiology

Volumn 51, Issue 5, 2011, Pages 812-820

  Gaffin, Robert D ^a   Peña, James R ^b   Alves, Marco S L ^a   Dias, Fernando A L ^b   Chowdhury, Shamim A K ^a   Heinrich, Lynley S ^a   Goldspink, Paul H ^b   Kranias, Evangelia G ^c   Wieczorek, David F ^c   Wolska, Beata M ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiac function; Diastolic dysfunction; Extracellular signal regulated kinase; Familial hypertrophic cardiomyopathy; Interstitial fibrosis; Phospholamban

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TROPOMYOSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATRIAL NATRIURETIC FACTOR GENE; BETA MYOSIN HEAVY CHAIN GENE; BODY WEIGHT; CALCIUM TRANSPORT; CARDIAC REMODELING; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; GENE DELETION; GENE EXPRESSION; HEART FUNCTION; HEART LEFT VENTRICLE DP-DT; HEART MUSCLE FIBROSIS; HEART WEIGHT; MARKER GENE; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SARCOPLASMIC RETICULUM; TRANSTHORACIC ECHOCARDIOGRAPHY;

ANIMALS; BIOLOGICAL MARKERS; BODY WEIGHT; CALCIUM; CALCIUM-BINDING PROTEINS; CARDIOMYOPATHY, HYPERTROPHIC, FAMILIAL; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION; HUMANS; MICE; MICE, TRANSGENIC; MUTATION; MYOCARDIAL CONTRACTION; MYOCARDIUM; ORGAN SIZE; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; SARCOPLASMIC RETICULUM; TROPOMYOSIN;

ADENOVIRIDAE; MUS; MUS MUSCULUS;

EID: 80053236880     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.07.026     Document Type: Article

References (55)

1. Seidman J.G., Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 2001, 104(4):557-567.
2. Seggewiss H., Blank C., Pfeiffer B., Rigopoulos A. Hypertrophic cardiomyopathy as a cause of sudden death. Herz 2009, 34(4):305-314.
3. Maron B.J. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002, 287(10):1308-1320.
4. Thierfelder L., Watkins H., MacRae C., Lamas R., McKenna W., Vosberg H.P., et al. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 1994, 77(5):701-712.
5. Tardiff J.C. Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex cardiovascular phenotypes. Heart Fail Rev 2005, 10(3):237-248.
6. Rodriguez J.E., McCudden C.R., Willis M.S. Familial hypertrophic cardiomyopathy: basic concepts and future molecular diagnostics. Clin Biochem 2009, 42(9):755-765.
7. Geisterfer-Lowrance A.A., Kass S., Tanigawa G., Vosberg H.P., McKenna W., Seidman C.E., et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell 1990, 62(5):999-1006.
8. Thierfelder L., MacRae C., Watkins H., Tomfohrde J., Williams M., McKenna W., et al. A familial hypertrophic cardiomyopathy locus maps to chromosome 15q2. Proc Natl Acad Sci USA 1993, 90(13):6270-6274.
9. Alves M.L., Gaffin R.D., Wolska B.M. Rescue of familial cardiomyopathies by modifications at the level of sarcomere and Ca2+ fluxes. J Mol Cell Cardiol 2010, 48(5):834-842.
10. Prabhakar R., Boivin G.P., Grupp I.L., Hoit B., Arteaga G., Solaro J.R., et al. A familial hypertrophic cardiomyopathy alpha-tropomyosin mutation causes severe cardiac hypertrophy and death in mice. J Mol Cell Cardiol 2001, 33(10):1815-1828.
11. Michele D.E., Gomez C.A., Hong K.E., Westfall M.V., Metzger J.M. Cardiac dysfunction in hypertrophic cardiomyopathy mutant tropomyosin mice is transgene-dependent, hypertrophy-independent, and improved by beta-blockade. Circ Res 2002, 91(3):255-262.
12. Jagatheesan G., Rajan S., Petrashevskaya N., Schwartz A., Boivin G., Arteaga G.M., et al. Rescue of tropomyosin-induced familial hypertrophic cardiomyopathy mice by transgenesis. Am J Physiol Heart Circ Physiol 2007, 293(2):H949-H958.
13. Coutu P., Bennett C.N., Favre E.G., Day S.M., Metzger J.M. Parvalbumin corrects slowed relaxation in adult cardiac myocytes expressing hypertrophic cardiomyopathy-linked alpha-tropomyosin mutations. Circ Res 2004, 94(9):1235-1241.
14. Pena J.R., Szkudlarek A.C., Warren C.M., Heinrich L.S., Gaffin R.D., Jagatheesan G., et al. Neonatal gene transfer of Serca2a delays onset of hypertrophic remodeling and improves function in familial hypertrophic cardiomyopathy. J Mol Cell Cardiol 2010, 993-1002.
15. MacLennan D.H., Kranias E.G. Phospholamban: a crucial regulator of cardiac contractility. Nat Rev 2003, 4(7):566-577.
16. Luo W., Grupp I.L., Harrer J., Ponniah S., Grupp G., Duffy J.J., et al. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ Res 1994, 75(3):401-409.
17. Hoit B.D., Khoury S.F., Kranias E.G., Ball N., Walsh R.A. In vivo echocardiographic detection of enhanced left ventricular function in gene-targeted mice with phospholamban deficiency. Circ Res 1995, 77(3):632-637.
18. Chu G., Ferguson D.G., Edes I., Kiss E., Sato Y., Kranias E.G. Phospholamban ablation and compensatory responses in the mammalian heart. Ann N Y Acad Sci 1998, 853:49-62.
19. Pan B.S., Hannon J.D., Wiedmann R., Potter J.D., Kranias E.G., Shen Y.T., et al. Effects of isoproterenol on twitch contraction of wild type and phospholamban-deficient murine ventricular myocardium. J Mol Cell Cardiol 1999, 31(1):159-166.
20. Schwinger R.H., Brixius K., Savvidou-Zaroti P., Bolck B., Zobel C., Frank K., et al. The enhanced contractility in phospholamban deficient mouse hearts is not associated with alterations in (Ca2+)-sensitivity or myosin ATPase-activity of the contractile proteins. Basic Res Cardiol 2000, 95(1):12-18.
21. Desai K.H., Schauble E., Luo W., Kranias E., Bernstein D. Phospholamban deficiency does not compromise exercise capacity. Am J Physiol Heart Circ Physiol 1999, 276(4):H1172-H1177.
22. Delling U., Sussman M.A., Molkentin J.D. Re-evaluating sarcoplasmic reticulum function in heart failure. Nat Med 2000, 6(9):942-943.
23. Freeman K., Lerman I., Kranias E.G., Bohlmeyer T., Bristow M.R., Lefkowitz R.J., et al. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest 2001, 107(8):967-974.
24. Minamisawa S., Hoshijima M., Chu G., Ward C.A., Frank K., Gu Y., et al. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 1999 Oct 29, 99(3):313-322.
25. Sato Y., Kiriazis H., Yatani A., Schmidt A.G., Hahn H., Ferguson D.G., et al. Rescue of contractile parameters and myocyte hypertrophy in calsequestrin overexpressing myocardium by phospholamban ablation. J Biol Chem 2001, 276(12):9392-9399.
26. Song Q., Schmidt A.G., Hahn H.S., Carr A.N., Frank B., Pater L., et al. Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy. J Clin Invest 2003, 111(6):859-867.
27. Georgakopoulos D., Mitzner W.A., Chen C.H., Byrne B.J., Millar H.D., Hare J.M., et al. In vivo murine left ventricular pressure-volume relations by miniaturized conductance micromanometry. Am J Physiol Heart Circ Physiol 1998, 274(4):H1416-H1422.
28. Pacher P., Nagayama T., Mukhopadhyay P., Batkai S., Kass D.A. Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc 2008, 3(9):1422-1434.
29. Rajan S., Jagatheesan G., Karam C.N., Alves M.L., Bodi I., Schwartz A., et al. Molecular and functional characterization of a novel cardiac-specific human tropomyosin isoform. Circulation 2010, 121(3):410-418.
30. Prabhakar R., Petrashevskaya N., Schwartz A., Aronow B., Boivin G.P., Molkentin J.D., et al. A mouse model of familial hypertrophic cardiomyopathy caused by a alpha-tropomyosin mutation. Mol Cell Biochem 2003 Sep, 251(1-2):33-42.
31. Nagueh S.F., Appleton C.P., Gillebert T.C., Marino P.N., Oh J.K., Smiseth O.A., et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009, 22(2):107-133.
32. Patel R., Nagueh S.F., Tsybouleva N., Abdellatif M., Lutucuta S., Kopelen H.A., et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001, 104(3):317-324.
33. Abhayaratna W.P., Seward J.B., Appleton C.P., Douglas P.S., Oh J.K., Tajik A.J., et al. Left atrial size: physiologic determinants and clinical applications. J Am Coll Cardiol 2006, 47(12):2357-2363.
34. Pritchett A.M., Mahoney D.W., Jacobsen S.J., Rodeheffer R.J., Karon B.L., Redfield M.M. Diastolic dysfunction and left atrial volume: a population-based study. J Am Coll Cardiol 2005, 45(1):87-92.
35. Brittsan A.G., Kranias E.G. Phospholamban and cardiac contractile function. J Mol Cell Cardiol 2000, 32(12):2131-2139.
36. Agrawal R., Agrawal N., Koyani C.N., Singh R. Molecular targets and regulators of cardiac hypertrophy. Pharmacol Res 2010, 61(4):269-280.
37. Heineke J., Molkentin J.D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev 2006, 7(8):589-600.
38. Clerk A., Cullingford T.E., Fuller S.J., Giraldo A., Markou T., Pikkarainen S., et al. Signaling pathways mediating cardiac myocyte gene expression in physiological and stress responses. J Cell Physiol 2007, 212(2):311-322.
39. Bueno O.F., De Windt L.J., Tymitz K.M., Witt S.A., Kimball T.R., Klevitsky R., et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 2000, 19(23):6341-6350.
40. Wolska B.M., Stojanovic M.O., Luo W., Kranias E.G., Solaro R.J. Effect of ablation of phospholamban on dynamics of cardiac myocyte contraction and intracellular Ca2+. Am J Physiol Cell Physiol 1996 Jul, 271(1):C391-C397.
41. Berridge M.J. Remodelling Ca2+ signalling systems and cardiac hypertrophy. Biochem Soc Trans 2006, 34(2):228-231.
42. Abraham S.T., Benscoter H.A., Schworer C.M., Singer H.A. A role for Ca2+/calmodulin-dependent protein kinase II in the mitogen-activated protein kinase signaling cascade of cultured rat aortic vascular smooth muscle cells. Circ Res 1997, 81(4):575-584.
43. De Koninck P., Schulman H. Sensitivity of CaM kinase II to the frequency of Ca2+ oscillations. Science 1998, 279(5348):227-230.
44. Janczewski A.M., Zahid M., Lemster B.H., Frye C.S., Gibson G., Higuchi Y., et al. Phospholamban gene ablation improves calcium transients but not cardiac function in a heart failure model. Cardiovasc Res 2004, 62(3):468-480.
45. Zhang T., Guo T., Mishra S., Dalton N.D., Kranias E.G., Peterson K.L., et al. Phospholamban ablation rescues sarcoplasmic reticulum Ca(2+) handling but exacerbates cardiac dysfunction in CaMKIIdelta(C) transgenic mice. Circ Res 2010, 106(2):354-362.
46. Dieterle T., Meyer M., Gu Y., Belke D.D., Swanson E., Iwatate M., et al. Gene transfer of a phospholamban-targeted antibody improves calcium handling and cardiac function in heart failure. Cardiovasc Res 2005, 67(4):678-688.
47. del Monte F., Harding S.E., Dec G.W., Gwathmey J.K., Hajjar R.J. Targeting phospholamban by gene transfer in human heart failure. Circulation 2002, 105(8):904-907.
48. Blanchard E., Seidman C., Seidman J.G., LeWinter M., Maughan D. Altered crossbridge kinetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. Circ Res 1999, 84(4):475-483.
49. Golitsina N., An Y., Greenfield N.J., Thierfelder L., Iizuka K., Seidman J.G., et al. Effects of two familial hypertrophic cardiomyopathy-causing mutations on alpha-tropomyosin structure and function. Biochemistry 1997, 36(15):4637-4642.
50. Bing W., Redwood C.S., Purcell I.F., Esposito G., Watkins H., Marston S.B. Effects of two hypertrophic cardiomyopathy mutations in alpha-tropomyosin, Asp175Asn and Glu180Gly, on Ca2+ regulation of thin filament motility. Biochem Biophys Res Commun 1997, 236(3):760-764.
51. Haghighi K., Kolokathis F., Pater L., Lynch R.A., Asahi M., Gramolini A.O., et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest 2003, 111(6):869-876.
52. Schmidt U., Hajjar R.J., Kim C.S., Lebeche D., Doye A.A., Gwathmey J.K. Human heart failure: cAMP stimulation of SR Ca(2+)-ATPase activity and phosphorylation level of phospholamban. Am J Physiol Heart Circ Physiol 1999, 277(2):H474-H480.
53. 2+-exchanger protein levels and diastolic function of failing human myocardium. Circulation 1999, 99(5):641-648.
54. Arai M., Matsui H., Periasamy M. Sarcoplasmic reticulum gene expression in cardiac hypertrophy and heart failure. Circ Res 1994, 74(4):555-564.
55. Hajjar R.J., Zsebo K., Deckelbaum L., Thompson C., Rudy J., Yaroshinsky A., et al. Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail 2008, 14(5):355-367.